课题基金 / 基金详情

The preventive and therapeutic potential of reducing mitochondrial H2O2 for AD

The preventive and therapeutic potential of reducing mitochondrial H2O2 for AD
减少线粒体 H2O2 对 AD 的预防和治疗潜力
批准号:
7683614
负责人:
QITAO RAN
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-01 至 2012-03-31

项目摘要

项目成果

QITAO RAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Abstract H2O2 is a major form of reactive oxygen species (ROS) produced by mitochondria. Recent data indicate that increased mitochondrial H2O2 is associated with pathogenesis of Alzheimer's disease (AD) and could facilitate AD pathogenesis by inducing oxidative damage and by altering cell signaling to affect amyloidogenesis. Although targeted removal of mitochondrial ROS has been proposed as a preventive/therapeutic strategy for AD, whether reducing mitochondrial H2O2 can retard pathogenesis of AD is unknown. Peroxiredoxin 3 (Prdx3/Prx3) is a peroxidase specializing in scavenging H2O2 in mitochondria and is also implicated to be important for protection against neurodegenerative diseases. We have recently generated transgenic mice overexpressing Prdx3, and our data indicate that transgenic mice overexpressing Prdx3 have reduced mitochondrial H2O2 levels that are correlated with reduced mitochondrial oxidative damage and decreased activities of 2- and 3- secretases in brain. Thus, our results indicate that overexpression of Prdx3 is effective in reducing mitochondrial H2O2 and that transgenic mice overexpressing Prdx3 will allow us to test the preventive and therapeutic potential of reducing mitochondrial H2O2 for AD. Using APP transgenic mice overexpressing Prdx3 in this project, we will test the following hypothesis: reducing mitochondrial H2O2 by overexpression of Prdx3 will improve mitochondria functions, ameliorate cognition impairment and reduce amyloidogenesis. The hypothesis will be tested in four Specific Objectives: 1. To determine if reducing mitochondrial H2O2 improves mitochondria functions in APP transgenic mice. 2. To determine if reducing mitochondrial H2O2 reduces oxidative damage and changes cell signaling in APP transgenic mice. 3. To determine if reducing mitochondrial H2O2 ameliorates cognitive impairment and decreases amyloidogenesis in APP transgenic mice. 4. To determine if reducing mitochondrial H2O2 can retard progression of AD after the onset of disease. In Specific Objective 4, a novel APP transgenic mouse model with inducible overexpression of Prdx3 will be generated and used to determine whether overexpressing of Prdx3 can slow or reverse the progression of cognition deficit and A( accumulation after the development of these adverse phenotypes. The data collected from this project will provide the first direct evidence about whether reducing mitochondrial H2O2 is effective for retarding AD pathogenesis and whether Prdx3 could serve as a target for AD prevention and therapy. Alzheimer's disease is of special importance to the veteran population because the incidence of Alzheimer's disease appears to be elevated by conditions encountered by our service men and women during deployment such as traumatic brain injury. Data collected in this study may lead to new preventive and therapeutic approaches for AD, which will benefit our military service men and women. 1 PUBLIC HEALTH RELEVANCE: Project Narrative Increased risk of Alzheimer's disease is a serious concern for our military service men and women. This study is designed to test the effectiveness of a novel prevention and therapy strategy for Alzheimer's disease. 1
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigation of Ferroptosis as a Therapeutic Target for ALS
Membrane lipid peroxidation in pathogenesis of Alzheimer’s disease
Membrane lipid peroxidation in pathogenesis of Alzheimer’s disease
Gpx4 and ferroptosis inhibition in retarding ALS
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: